CAAs enhance the release of leptin to increase the expression of HER2 and heat-shock protein 90 (Hsp90) by activating the JAK/STAT3 signaling pathways, which reduces sensitivity to tamoxifen in ER+ BC. Here, ERBB2 is linked to breast cancer.